Loading
CSF2RB (Cytokine receptor common subunit beta) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Sarcomas, Leukaemia, Myeloproliferative neoplasms and 1 more.
Cell surface receptor that plays a role in immune response and controls the production and differentiation of haematopoietic progenitor cells into lineage-restricted cells. Acts by forming an heterodimeric receptor through interaction with different partners such as IL3RA, IL5RA or CSF2RA. In turn, participates in various signalling pathways including interleukin-3, interleukin-5 and granulocyte-macrophage colony-stimulating factor/CSF2 pathways.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Doxorubicin. Open Targets scores its association with cancer at 0.55 (direct and indirect evidence; datatypes literature 0.67, animal model 0.45, genetic association 0.00, clinical 0.86).
In plain words · CSF2RB (Cytokine receptor common subunit beta) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Sarcomas, Leukaemia, Myeloproliferative neoplasms and 1 more.
CSF2RB (Cytokine receptor common subunit beta) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Sarcomas, Leukaemia, Myeloproliferative neoplasms and 1 more.
Cell surface receptor that plays a role in immune response and controls the production and differentiation of haematopoietic progenitor cells into lineage-restricted cells.
No product in this corpus aims at CSF2RB yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA CSF2RB: RNA tissue enhanced (bone marrow 51 nTPM, lymphoid tissue 62 nTPM); blood lineage lineage enriched (granulocytes 239 nTPM); no normal tissue stained high. Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Sarcomas (soft tissue, bone, GIST), Leukaemia, Myeloid neoplasms); Open Targets associates it with 1 specific cancer type at or above 0.5 (acute myeloid leukemia). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas CSF2RB tissue; Open Targets ENSG00000100368 associations
First described 1990. Earliest sequence paper UniProt cites for the protein: Hayashida et al, Proc. Natl. Acad. Sci. U.S.A, 1990, "Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF): reconstitution of a high-affinity GM-CSF receptor". Source.
Sources: HGNC HGNC:2436 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P32927 (protein name, function text, keywords and locations (REST API)); CIViC gene CSF2RB (1 evidence items, 0 assertions, 1 variants; diseases: Sarcoma (GraphQL API, CC0)); Open Targets ENSG00000100368 (association with cancer (MONDO_0004992) 0.55; per-cancer scores at or above 0.5: acute myeloid leukaemia 0.52, myeloproliferative neoplasm 0.53, leukaemia 0.54 (GraphQL API, CC0))
Cell surface receptor that plays a role in immune response and controls the production and differentiation of haematopoietic progenitor cells into lineage-restricted cells. Acts by forming an heterodimeric receptor through interaction with different partners such as IL3RA, IL5RA or CSF2RA. In turn, participates in various signalling pathways including interleukin-3, interleukin-5 and granulocyte-macrophage colony-stimulating factor/CSF2 pathways. In unstimulated conditions, interacts constitutively with JAK1 and ligand binding leads to JAK1 stimulation and subsequent activation of the JAK-STAT pathway. Location: Membrane (UniProt). Locus 22q12.3 (HGNC).
RNA: tissue enhanced (bone marrow 51 nTPM, lymphoid tissue 62 nTPM), detected in many normal tissues. Blood: lineage enriched (granulocytes 239 nTPM).
No normal tissue stained high.
No cancer sample stained medium or high.
HPA CSF2RB tissue · HPA CSF2RB pathology · HPA protein class: CD markers, FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CSF2RB" OR ABSTRACT:"CSF2RB" OR TITLE:"colony stimulating factor 2 receptor subunit beta" OR ABSTRACT:"colony stimulating factor 2 receptor subunit beta" OR TITLE:"Cytokine receptor common subunit beta" OR ABSTRACT:"Cytokine receptor common subunit beta" OR TITLE:"IL5RB" OR ABSTRACT:"IL5RB" OR TITLE:"CD131" OR ABSTRACT:"CD131" OR TITLE:"betaGMR" OR ABSTRACT:"betaGMR") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CSF2RB, not a curated reading list.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), CIViC, Acute myeloid leukaemia.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), CIViC, Acute myeloid leukaemia.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), CIViC, Acute myeloid leukaemia.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), CIViC, Acute myeloid leukaemia.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.